Peter Laszlo Lakatos
Semmelweis Egyetem
H-index: 83
Europe-Hungary
Top articles of Peter Laszlo Lakatos
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study | Digestive and Liver Disease | Panu Wetwittayakhlang Khaled Karkout Arti Wongcha-Um Paraskevi Tselekouni Reem Al-Jabri | 2024/1/1 |
P412 Faecal Calprotectin as a predictor of endoscopic and histologic remission in patients with Ulcerative Colitis | Journal of Crohn's and Colitis | G Drügg Hahn C Flores W Afif G Wild A Bitton | 2024/1/1 |
EPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASE AMONG EARLY-INDUSTRIALIZED REGIONS OF THE WORLD: CHALLENGES IN SUSTAINABLE HEALTHCARE DELIVERY | Gastroenterology | Michelle Herauf Stephanie Coward Juan Nicolas Pena-Sanchez Charles Bernstein Eric Benchimol | 2024/2/1 |
Burden of perianal disease in Crohn's disease: Accelerating medical therapy and high rates of perianal surgery over the last four decades–Results from a population‐based study … | Alimentary Pharmacology & Therapeutics | Lorant Gonczi Laszlo Lakatos Petra A Golovics Dorottya Angyal Fruzsina Balogh | 2024/3/1 |
Stable incidence and risk factors of colorectal cancer in ulcerative colitis: A population-based cohort between 1977–2020 | Clinical Gastroenterology and Hepatology | Panu Wetwittayakhlang Petra A Golovics Lorant Gonczi Laszlo Lakatos Peter L Lakatos | 2024/1/1 |
P356 Long-term outcome of UC patients in clinical remission with different level of mucosal activity: real world, retrospective, multicontinental study | Journal of Crohn's and Colitis | P Bacsur P Wetwittayakhlang T Resál B Farkas M Rutka | 2024/1/1 |
Current Evidence for Combined Targeted Therapy for the Treatment of Inflammatory Bowel Disease | Panu Wetwittayakhlang Peter L Lakatos | 2024/2/1 | |
The prevalence and outcomes of perianal Crohn's disease across the treatment eras—Authors' reply | Lorant Gonczi Laszlo Lakatos Akos Ilias Peter L Lakatos | 2024/3 | |
Burden of Mental Health among Patients with Inflammatory Bowel Disease—A Cross-Sectional Study from a Tertiary IBD Center in Hungary | Journal of Clinical Medicine | Livia Lontai Lívia Priyanka Elek Fruzsina Balogh Dorottya Angyal Péter Pajkossy | 2024/3/29 |
P716 Efficacy and safety of upadacitinib during induction in Crohn’s disease: Real-world experience | Journal of Crohn's and Colitis | R Jairath A Zoughlami N Pilote W Afif A Bitton | 2024/1/1 |
Efficacy and Safety of Upadacitinib During Induction in Crohn’s disease: Real-World Experience | Rishi Jairath Amine Zoughlami Nicolas Pilote Waqqas Afif Alain Bitton | 2024/1/24 | |
A Commentary on the Epidemiology of Inflammatory Bowel Disease in Compounding Prevalence Nations: Towards Sustaining Healthcare Delivery | Gastroenterology | Michelle Herauf Stephanie Coward Juan-Nicolás Peña-Sánchez Charles N Bernstein Eric I Benchimol | 2024/2/18 |
Unravelling the Smoke Trail: Maternal Smoking, Childhood Exposure, and their Impact on Inflammatory Bowel Diseases | Panu Wetwittayakhlang Peter L Lakatos | 2024/3/18 | |
P661 Ustekinumab in Crohn’s disease: A three-year multicentre prospective study from Hungary-Assessing efficacy, drug sustainability, and safety | Journal of Crohn's and Colitis | LJ Barkai L Gonczi K Farkas B Farkas T Molnar | 2024/1/1 |
The Global Evolution of Inflammatory Bowel Disease across Four Epidemiologic Stages | Gilaad Kaplan Lindsay Hracs Joseph Windsor Julia Gorospe Michael Cummings | 2024/1/23 | |
MODELING THE TRANSITION TO THE FOURTH EPIDEMIOLOGIC STAGE OF INFLAMMATORY BOWEL DISEASE: PREVALENCE EQUILIBRIUM | Inflammatory Bowel Diseases | Joseph Windsor Lindsay Hracs Michael Cummings Julia Gorospe Michael Buie | 2024/2/1 |
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years | Laszlo Jozsef Barkai Lorant Gonczi Fruzsina Balogh Dorottya Angyal Klaudia Farkas | 2024/3/13 | |
P1016 Real-world data on sequential therapy in moderate-to-severe UC: Unveiling second-line strategies after anti-TNF failure | Journal of Crohn's and Colitis | B Farkas M Borsos T Resál P Bacsur Z Szepes | 2024/1/1 |
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials | Panu Wetwittayakhlang Talat Bessissow Peter L Lakatos | 2024/1/12 | |
TRENDS IN INFLAMMATORY BOWEL DISEASE INCIDENCE AND PREVALENCE ACROSS EPIDEMIOLOGIC STAGES: A GLOBAL SYSTEMATIC REVIEW WITH META-ANALYSIS | Julia Gorospe Joseph Windsor Lindsay Hracs Stephanie Coward Michael Buie | 2024/2/1 |
Co-Authors
